Dismay over the price of prescription drugs continues to pervade politics and popular culture. Last year, the Inflation Reduction Act, with its Medicare Part D redesign and drug negotiation provisions, shifted the dynamics of the prescription drug market and policymakers continue to look for ways to address high drug costs. Proposed solutions include boosting competition by reducing paten abuses, increasing the number of biosimilars on the market, and exploring the role of pharmacy benefit companies (PBMs).
PCMA’s Policy Forum featured policymakers – including key Administration officials and Congressional staffers – and PBM executives to discuss how the public and private sectors are tackling drug costs and improving both the affordability and quality of care for patients. Speakers addressed topics highlighted in the PCMA Affordable Future policy platform, which focuses on increasing competition to bolster the private market, providing clinicians with data and tools to enhance patient care, and supporting and protecting patients.
